The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer Authors: Neal D Shore, Michael S Cookson, Eleni Efstathiou Published: 2024 ABSTRACT AbstractIn this podcast discussion, we review the landscape of androgen deprivation therapies (ADT) for the treatment of advanced prostate cancer. Prior to 2020, available ADT options to achieve chemical castration included gonadotropin-releasing hormone receptor agonists (e.g., leuprolide) and antagonists (e.g., degarelix) administered via muscular or subcutaneous injection. In 2020, the once-daily oral gonadotropin-releasing hormone antagonist, relugolix, received US regulatory approval for the treatment of advanced prostate cancer based on results from the Phase III HERO trial. In this podcast, we also discuss the primary efficacy and safety results of this trial, and key points for providers and patients to consider as they discuss the different ADT options. Podcast Discussion Dr. Shore: Hello everyone, I am Dr. Neal Shore and I'm very fortunate to be joined today by good friends and colleagues, Drs. Michael Cookson and Eleni Efstathiou. It is my pleasure to moderate this podcast discussion entitled “The landscape of androgen deprivation therapies [ADT] for the treatment of advanced prostate cancer.” In this episode, we will briefly review the landscape of ADT that were available prior to 2020 and discuss the primary efficacy and safety results of the Phase III HERO trial, which led to the approval of relugolix. This podcast is funded by Pfizer in collaboration with Sumitomo Pharma from Switzerland (Sumitomo Pharma Switzerland, GmbH). Medical writing and editorial assistance were funded by Pfizer in collaboration with Sumitomo Pharma of Switzerland. The HERO study was sponsored by Sumitomo Pharma and it was a great pleasure, and on behalf of myself and all the investigators, it is an honor to present that additional data. Author disclosures are included in the published podcast article. So, let’s begin. So, Dr. Efstathiou, would you please give us a brief overview of how androgen deprivation therapy (ADT) is used to treat advanced prostate cancer patients and the landscape of gonadotropin-releasing hormone (GnRH) receptor agonists and antagonists prior to 2020. Dr. Efstathiou: Yes, thank you, thank you very much, Dr. Shore, for including me in this podcast. And I think it is truly important to put things in context, so, let’s start with that. What was going on prior to 2020? I think most of us are familiar with the term androgen deprivation therapy or, as we call it endearingly, ADT. Nothing much endearing about it, but in any case, it is the type of treatment which is standard for advanced prostate cancer. What it aims to do is to deplete serum testosterone levels in order to get to our goal, which is to inhibit tumor growth. So, gonadotropin-releasing hormone agonists – GnRH agonists as we call them – such as goserelin, leuprolide, triptorelin, have historically been the most commonly used ADTs to achieve chemical castration. These ADTs are administered via intramuscular or subcutaneous injections, generally at 1-, 3-, 4-, 6- or 12-month intervals [1,2]. Now to the drawbacks of GnRH agonists. Of course, one of the main ones is that initial testosterone surge that may cause clinical flare and adverse events that are the on-target effect of testosterone suppression including fatigue, hot flashes, decreased libido, decreased bone mineral density, increased risk of adverse cardiovascular and metabolic events and prolonged testosterone suppression after treatment cessation [1–3]. Of note, we were on the same panel with Dr. Shore where such data were presented in detail by our colleagues, who showed that prolonged exposure to leuprolide can lead to non-reversible suppression of testosterone long term, even after cessation [4]. GnRH antagonists, on the other hand, rapidly suppress testosterone preventing surges and clinical flares. However, first- and second-generation GnRH antagonists demonstrated histamine-releasing properties, thus leading to potentially fatal anaphylaxis [2,5]. For those who have been in the field for a longer time, we know of such an agent that was initially approved in 2005 and then retracted from the market because of such events. Before 2020, the only GnRH antagonist that we had available, degarelix, was administered via monthly only subcutaneous injections, and it was the only GnRH antagonist available commercially for the treatment of patients with advanced prostate cancer. While, overall tolerability was found to be similar between degarelix and the GnRH agonist leuprolide, injection site reactions were more common with degarelix: 35% versus less than 1%, respectively [2]. Back to you, Dr. Shore. Dr. Shore: Yeah, I think those are some great points. That’s a really, very good summary. I think, you know, the mechanism of action of an antagonist as opposed to an agonist has been an ongoing discussion. You are trying to lower the testosterone quickly and not have that potential surge-flare phenomena as you describe, and I do think the injection site reactions of about 35% of patients, was problematic for some patients in clinics. In December 2020, during the pandemic, the once-daily oral GnRH antagonist, relugolix, was approved by the US FDA [Food and Drug Administration] for treatment of advanced prostate cancer based on the primary results from the Phase III HERO trial [6], which we presented at plenary presentations in 2020 at AUA [American Urological Association] and at ASCO [American Society of Clinical Oncology], of course, virtually, as we were not able to do things in person back then, but it was a great honor that we had plenaries at both of those 2020 important congresses. So, with that, let me ask you, Dr. Cookson, what were the key efficacy and safety findings from this HERO trial? Dr. Cookson: Thank you, Dr. Shore, and thanks for mentioning, you know, the difficulties with the presentation of data and good results at the end of and during the pandemic. In the HERO trial, relugolix, which was a 2:1 randomization, so there were like 622 patients. This was an oral agent, so it was 120 mg taken once daily after a single loading dose, which was 360 mg [7]. And in this study, they demonstrated both non-inferiority and superiority as compared with leuprolide, in where there were 308 patients and those patients underwent administration of intramuscular or subcutaneous injections every 3 months [7]. And again, I mentioned to you non-inferiority and superiority as compared with leuprolide on the primary efficacy end point of sustained testosterone suppression below castrate levels; and in this study, defined as <50 ng/dl from day 28 through week 48 of treatment, and by comparison, it was 97% for the relugolix [group] as compared with 89% for the leuprolide [group]. That was a highly positive statistical p-value of <0.001 [7]. Key secondary endpoints also demonstrated superiority of relugolix over leuprolide with statistically significant p-values of <0.001 and these included: first, testosterone suppression to profound castrate levels and that was defined as <20 ng/dl on day 15, and that was 78% in the relugolix [group] as compared with only 1% in the leuprolide group [7]. Second, percentage of patients with confirmed prostate-specific antigen or PSA response at day 15 with day 29 confirmation. And again, this occurred in 79% of the relugolix [arm] as compared with 20% in the leuprolide arm. And third, the mean follicular-stimulating hormone levels at end of week 24 and that was defined as 1.72 versus 5.95 IU/l. Also, in a post hoc subgroup analysis, the percent of patients with testosterone recovery – this is important – to baseline or at least 280 ng/dl 90 days after treatment cessation was 54% in the relugolix cohort versus 3% in the leuprolide cohort [7]. You mentioned the key safety results: overall incidence of adverse events or AEs was consistent between the relugolix and the leuprolide treatment cohorts. Ninety-three [percent] and 94% of patients in the relugolix and leuprolide cohorts reported any AE, respectively [7]. AEs that occurred in >10% of patients in either cohort included hot flash, fatigue, constipation, diarrhea, arthralgia and hypertension. The hot flash, the most common AE, was reported in 54% and 52% of patients in the relugolix and the leuprolide cohorts, respectively. Diarrhea was reported in a higher percentage of patients treated with relugolix versus leuprolide, and that was 12% in the relugolix [cohort] as compared with 7% in the leuprolide [cohort]; but all cases were mild or moderate [7]. In an exploratory analysis, the incidence rate of major adverse cardiovascular events was 54% lower in the relugolix cohort versus the leuprolide cohort, and that was 3% versus 6% overall [7]. Dr. Shore: Well, thanks very much, Dr. Efstathiou for setting the table for us and understanding the, where we were, have been and how, where we have gone to with the HERO trial that Dr. Cookson just did a wonderful job in reviewing in a very concise fashion. ADT with GnRH agonist or antagonists has been the mainstay of treatment for advanced prostate cancer. We are now moving into other areas such as androgen receptor pathway inhibitors – that is a discussion for another topic. But interesting, the androgen receptor pathway inhibitor drugs are oral, they are all oral. And here we now have relugolix, a GnRH antagonist, it is the only once-daily, oral ADT approved for the treatment of advanced prostate cancer in the United States. As Dr. Cookson very nicely articulated, the results of the Phase III trial demonstrate that relugolix, a GnRH antagonist, achieved rapid, sustained suppression of testosterone to castrate levels that was superior to that with leuprolide. Relugolix also showed a trend toward a higher percentage of patients with testosterone recovery 90 days post-treatment cessation and a 54% lowering of the risk of major adverse cardiovascular events compared with leuprolide; and this was all based on the data generated from the HERO trial, which we published in the New England Journal [of Medicine] [7]. To determine the best treatment approach for individuals with advanced prostate cancer, providers and patients, along with their caregivers, should discuss the modes of administration – parenteral, IM [intramuscular], subQ [subcutaneous], oral – dosing schedules, the different depot formulations versus an oral once-a-day pill, and the safety and efficacy profiles of these different ADT options [8,9]. Shared decision-making is really front and center these days and it is important to have that full-throated discussion with patients and their caregivers. These safety and efficacy results are important, but are not the only factors to consider when choosing the optimal prostate cancer treatment for individual patients; patient preferences, costs and adherence rates are also important considerations [8]. A 2023 cost-effective analysis did not find relugolix cost-effective compared with leuprolide from a healthcare payer’s perspective, though this result changed if the willingness-to-pay threshold was increased; additionally, the analysis did not take into account the potential influence of adverse events [9]. Our discussion today is focused on the landscape of GnRH agonists and antagonists for the treatment of advanced prostate cancer, as well as the primary results from the HERO study, which – I think for all of us who have been a part of that – we are very proud of that work. Future episodes will cover other topics such as testosterone control and recovery post cessation of androgen deprivation therapy; relugolix combination therapy, specifically with the androgen receptor pathway inhibitor drugs and even with chemotherapy; patient preferences for different ADT options, this goes back to the very contemporaneously important notion of shared decision-making; as well as we will have an opportunity to review ongoing clinical trials and real-world studies. So, I again thank you so much Drs. Efstathiou and Cookson, and thank you all for listening. Supplementary Material Supplemental Material Supplemental Material